Effect and cardiovascular safety of adding rosiglitazone to insulin therapy in type 2 diabetes: A meta-analysis.

J Diabetes Investig · 2015 · PMC4296706 · PMID 25621136

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

borderline significantP = 0.06so close (0.05 < p ≤ 0.1)

A meta-analysis by Nissen and Wolski including 42 trials with a duration of more than 24 weeks involving patients with type 2 diabetes, Alzheimer's disease and psoriasis reported a significant 43% increase risk of MI (odds ratio [OR] 1.43, 95% CI 1.03–1.98, P = 0.03) with rosiglitazone, with a borderline significant 64% increased risk in CV death (OR 1.64, 95% CI 0.98–2.74, P = 0.06) 26 .

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.